Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of pdl-1 antibody, its pharmaceutical composition and its use

A PDL-1, antibody technology, applied in the field of tumor therapy and molecular immunology, can solve the problem of decreased expression of T cell surface activation markers

Active Publication Date: 2018-08-28
SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that the PDL-1 / B7-1 complex is also a negative signal for T cell activation, and the combination of the two can lead to a decrease in the expression of T cell surface activation markers, inhibit T cell proliferation, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pdl-1 antibody, its pharmaceutical composition and its use
  • A kind of pdl-1 antibody, its pharmaceutical composition and its use
  • A kind of pdl-1 antibody, its pharmaceutical composition and its use

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0164] Preparation Example 1: Preparation of Fusion Protein PDL-1ECD-mFc

[0165] 1. Synthesis of gene PDL-1ECD-mFc

[0166] For the extracellular fragment PDL-1ECD (programmed cell death 1ligand 1, NCBIGenBank ID: NP_054862.1) of the gene PDL-1, PDL-1 and PD-L1 can be used interchangeably in scientific literature, and PDL-1 is used uniformly in this paper. The corresponding amino acid sequence is fused with the Fc protein fragment (mFc) of mouse IgG. In order to improve the expression efficiency of the target gene in the 293f cell expression system, GenScript was commissioned to optimize the nucleic acid sequence corresponding to the protein sequence, and GenScript was commissioned to synthesize the corresponding fusion protein gene.

[0167] 2. Acquisition of pUC57simple-PDL-1ECD-mFc plasmid:

[0168]The synthetic PDL-1ECD-mFc fusion gene was cloned by GenScript into the pUC57simple (provided by GenScript) expression vector to obtain the pUC57simple-PDL-1ECD-mFc plasmid....

preparation example 2

[0173] Preparation Example 2: Preparation of Fusion Protein PD-1-hFc

[0174] 1. Synthesis of gene PD-1-hFc

[0175] The amino acid sequence corresponding to the extracellular fragment PD-1ECD (Programmed cell death protein 1, NCBI GenBank ID: NP_005009.2) of the gene PD-1 was fusion designed with the Fc protein fragment (hFc) of human IgG. In order to improve the expression efficiency of the target gene in the 293f cell expression system, GenScript was commissioned to optimize the nucleic acid sequence corresponding to the protein sequence, and GenScript was commissioned to synthesize the corresponding fusion protein gene.

[0176] 2. Acquisition of pUC57simple-PD-1ECD-TEV-hFc plasmid

[0177] The PD-1ECD-TEV-hFc fusion gene synthesized by GenScript was cloned into the pUC57simple (provided by GenScript) expression vector to obtain the pUC57simple-PD-1ECD-TEV-hFc plasmid.

[0178] 3. Construction of pcDNA3.1-PD-1ECD-TEV-hFc recombinant plasmid

[0179] The plasmid pUC57s...

preparation example 3

[0182] Preparation Example 3: Preparation of B7-1-hFc

[0183] 1. Synthesis of gene B7-1-hFc

[0184] The amino acid corresponding to the extracellular fragment B7-1ECD of gene B7-1 (Cluster of Differentiation 80 (also CD80and B7-1), NCBIGenBank ID: NP_005182.1) was fusion designed with the Fc protein fragment (hFc) of human IgG. In order to improve the expression efficiency of the target gene in the 293f cell expression system, GenScript was commissioned to optimize the nucleic acid sequence corresponding to the protein sequence, and GenScript was commissioned to synthesize the corresponding fusion protein gene.

[0185] 2. Acquisition of pUC57simple-B7-1ECD-hFc plasmid

[0186] The B7-1ECD-hFc fusion gene synthesized by GenScript was cloned into the pUC57simple (provided by GenScript) expression vector to obtain the pUC57simple-B7-1ECD-hFc plasmid.

[0187] 3. Construction of pcDNA3.1-B7-1ECD-hFc recombinant plasmid

[0188] The plasmid pUC57simple-B7-1ECD-hFc was diges...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is a monoclonal antibody against programmed cell death 1 ligand (PDL-1) or an antigen-binding fragment thereof, the monoclonal antibody can specifically bind to PDL-1, and relieve the inhibition of PDL-1 on the body's immunity , thereby activating T lymphocytes. The pharmaceutical composition and application comprising the monoclonal antibody are also provided.

Description

technical field [0001] The invention belongs to the fields of tumor treatment and molecular immunology, and relates to an anti-PDL-1 antibody, its pharmaceutical composition and its application. Specifically, the present invention relates to an anti-PDL-1 monoclonal antibody. Background technique [0002] PD-1 / PDL-1 signaling pathway plays an important role in regulating immune tolerance, microbial infection and tumor immune escape. The expression of PD-1 (programmed cell death 1, programmed cell death factor 1) is mainly in immune cells such as T cells, and the ligand of PD-1, PDL-1, is mainly highly expressed in many human tumor tissues. Immunohistochemical methods have been used in breast cancer, lung cancer, gastric cancer, intestinal cancer, esophageal cancer, ovarian cancer, cervical cancer, kidney cancer, bladder cancer, pancreatic cancer, glioma, melanoma and other human tumors. The expression of PDL-1 protein was detected in tissues, and the expression level of PD...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N15/13C12N5/20A61K39/395A61P35/00
CPCC07K16/2827G01N33/57407G01N33/57411G01N33/57446G01N33/577G01N33/68A61P7/06A61P35/02A61P35/00A61K2039/505C07K2317/56C07K2317/565C07K2317/92A61K39/395C07K14/70532C07K2317/24C07K2317/33C07K2317/52C07K2317/76C07K2319/50C07K2319/30C12N5/16C07K2317/734C07K2317/732C07K2317/31C07K16/2896C07K16/462C07K16/468A61K47/6803C07K2317/51C07K2317/515
Inventor 李百勇薛彤彤夏瑜王忠民肖亮王利春王晶翼
Owner SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD